BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1935 related articles for article (PubMed ID: 31342797)

  • 21. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
    Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
    Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. State of the art in CAR T cell therapy for CD19+ B cell malignancies.
    Frigault MJ; Maus MV
    J Clin Invest; 2020 Apr; 130(4):1586-1594. PubMed ID: 32235098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
    J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.
    Ghobadi A
    Curr Res Transl Med; 2018 May; 66(2):43-49. PubMed ID: 29655961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
    Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
    Front Immunol; 2021; 12():681984. PubMed ID: 34248965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor T-cell therapies for lymphoma.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system.
    Zhang W; Jordan KR; Schulte B; Purev E
    Drug Des Devel Ther; 2018; 12():3343-3356. PubMed ID: 30323566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
    Scarfò I; Ormhøj M; Frigault MJ; Castano AP; Lorrey S; Bouffard AA; van Scoyk A; Rodig SJ; Shay AJ; Aster JC; Preffer FI; Weinstock DM; Maus MV
    Blood; 2018 Oct; 132(14):1495-1506. PubMed ID: 30089630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.
    Myers GD; Verneris MR; Goy A; Maziarz RT
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33846220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
    Jain T; Sauter CS; Shah GL; Maloy MA; Chan J; Scordo M; Avecilla ST; Batlevi Y; Dahi PB; Batlevi CW; Lia Palomba M; Giralt SA; Perales MA
    Leukemia; 2019 Oct; 33(10):2540-2544. PubMed ID: 31114023
    [No Abstract]   [Full Text] [Related]  

  • 37. Updates on CAR T-cell therapy in B-cell malignancies.
    Jacoby E; Shahani SA; Shah NN
    Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research Techniques Made Simple: CAR T-Cell Therapy.
    Siddiqi HF; Staser KW; Nambudiri VE
    J Invest Dermatol; 2018 Dec; 138(12):2501-2504.e1. PubMed ID: 30243656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
    Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
    J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
    Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S
    Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 97.